EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

HBM Healthcare Investments (HBMN) fair value: what the stock is really worth

As of Sep 23, 2026: fair value of HBM Healthcare Investments CHF 379, price CHF 227, upside +67.2%, quality 79 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? Yes
  2. Good quality? Yes
  3. Add to watchlist

Financial Services · CH · ISIN CH0012627250

HH Some data Sep 24, 2026

HBM Healthcare Investments

HBMN · SW

Strongly undervaluedStrong Fair Value upside with high Quality.

Fair value CHF 379.49 · Strongly undervalued (+67%)
Quality 79/100
!Weak Growth (revenue 5y −18.6 %/yr)
Highly profitable · 98.6% net margin (TTM)
!Low debt · negative free cash flow
·3.96% dividend yield
Ranks above peers (10/13)
Wide moat 76/100
!Evidence only medium, so the estimate is less certain
!The models disagree: range CHF 277.68 to CHF 1,286

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

CHF 298.16 CHF 129.20 Fair Value CHF 379.49 Jun 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

60‑month range CHF 129.20 – CHF 298.16 · fair‑value band CHF 277.68 – CHF 1,286 · the CHF 227.00 price screens below the CHF 379.49 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.

Follow HBM Healthcare Investments in your weekly email

Every Wednesday you see whether HBM Healthcare Investments is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

HBM Healthcare Investments AG specializes in fund of funds and direct investments in middle market and mature companies.

Show more

HBM Healthcare Investments AG specializes in fund of funds and direct investments in middle market and mature companies. The fund prefers to invest in start up, early stage, mid stage, mid venture, late venture, and late stage private companies, unlisted emerging companies, small cap public companies, buyouts, growth capital, and private investment in public equities (PIPES). Within fund of funds, it invests in venture capital funds. It also seeks to finance spin-offs of product lines or departments from larger corporations and the expansion or restructuring of established companies, seed stages, venture capital, expansion capital stages, spin-offs, and buyouts. The fund prefers to invest in the private and public companies in the healthcare sector with a focus on human medicine, drugs, pharma , biopharma, biotechnology, diagnostics, medical technology, and related industries. It seeks to make initial investments in companies whose primary products are in clinical development or the immediately preceding stage. The fund typically invests globally with a focus on Asia Pacific, Asia, North America, and Europe. In case of public companies, it focuses on those which originate from its private portfolio. The fund increases its investment in portfolio companies by participating in a follow-on financing or after the portfolio company's IPO. It may acquire majority participations in portfolio companies, usually takes a seat on the portfolio company's Board of Directors, and largely makes equity investments but may also invest through other instruments including convertible bonds, debt securities, structured products, and derivatives. The fund exits its portfolio companies through trade sale or IPO.

Stock analysis

HBM Healthcare Investments (HBMN) currently trades at CHF 227.00, while our model-based Fair Value estimate is CHF 379.49, implying the stock looks roughly 40.2% undervalued today.

Show more

Valuation

Bull case: the Earnings-Based group reads highest at a median of CHF 1,439 per share, and 5 of the 8 models we run sit above the CHF 227.00 price.

Bear case: the Dividend Discount group reads lowest at CHF 74.39, and 3 of the 8 models stay below the price. Evidence for this calculation is medium.

Scenario range: CHF 277.68 (bear) to CHF 1,286 (bull), the price of CHF 227.00 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 79/100 (high quality), in the Financial Services sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

HBM Healthcare Investments reported revenue of CHF 274M in FY2026 versus −CHF 76.5M in FY2022. Reported net income was CHF 272M in FY2026.

Key figures

Market cap CHF 1.7B · P/E ratio 5.6 · P/S ratio 5.52 · EPS (TTM) CHF 40.74 · Dividend yield 4.0% · Net margin 99.1% · Return on equity 15.6% · Return on assets (EBIT) −2.1%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 47 out of 100 (low confidence).

What moves the price

The share trades about 11% below its 52-week high and 34% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Financial Services peers we cover trades at −4% fair-value upside, at 67%, HBMN screens cheaper than that median.

Fair Value models

Bear CHF 277.68 Fair Value CHF 379.49 Bull CHF 1,286
Model Each model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2026 figures (about 6 months old). Earnings retained since then (CHF 15.39 per share) are deliberately not added. Bear Bear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull Bull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence Evidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
Gordon GGM CHF 43.20 CHF 86.08 CHF 130.35 63
DDM Multi-Stage CHF 43.20 CHF 74.39 CHF 90.86 63
P/E Multiple CHF 400.83 CHF 534.44 CHF 668.05 63
All 8 models by family
Earnings-Based
Graham-Dodd CHF 279.55 CHF 1,950 CHF 2,736 59
Lynch FV CHF 1,007 CHF 1,439 CHF 1,871 57
Dividend Discount
Gordon GGM CHF 43.20 CHF 86.08 CHF 130.35 63
DDM Multi-Stage CHF 43.20 CHF 74.39 CHF 90.86 63
Multiples
P/E Multiple CHF 400.83 CHF 534.44 CHF 668.05 63
P/B Multiple CHF 292.81 CHF 390.41 CHF 488.02 55
Asset-Based
NCAV (Graham) CHF 139.43 CHF 186.84 CHF 278.87 54
Economic Profit
Residual Income CHF 272.57 CHF 361.37 CHF 1,111 61

Open the full fair value analysis →

Notify me when HBMN reaches fair value

Put HBMN on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 79/100

Of which business quality 69 · Market factors (momentum, volatility) 70

Profitability 48
Margins and returns on capital today
Quality Growth 93
Are margins and returns improving?
Cashflow 42
Earnings quality: real cash, not paper profit
Fin. Strength 66
Balance sheet, leverage, solvency risk
Investment 97
Disciplined investing over empire-building
Low Volatility 83
Calm price path (market factor)
Momentum 59
Price trend over the last 3–12 months (market factor)
52W Momentum 71
Distance to the 52-week high (market factor)
Net Issuance 98
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality Growth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 20/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+1,126.7%
Revenue growth 5 years Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−18.6%
Start year 2021 (pandemic)
Revenue growth 24 years Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.5%
What shareholders gained per year (last 5 years) What the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−5.6%
Earnings growth per share plus dividend.
Earnings per share, growth per year−9.6%
Dividend (yield on the price)4.0%
Pace: 5 vs 10 years Two data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−10% vs 8%, slowing
Profit margin 2021 to 2026 Operating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.99% → −1%
Start year 2021 (pandemic)
⚠ Revenue per share shrinking 20.6%/yr over ~10Y (margins eroding too) Structural-decline marker: revenue PER SHARE has fallen over the last decade (robust median trend, not a single year). Backtested across 2005 to 2017, such businesses trailed the market by about 2.5 percentage points per year. Display only: it does not change the fair value or the quality score.

Watch HBMN, get fair value alerts →

Compare HBM Healthcare Investments with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Asset Management · 659 stocks

Beats the industry median on 10/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 77 · Top 25%
Fair Value upside +67% · Above median
Profitability
Return on equity (TTM) 16% · Top 25%
Return on assets 9% · Top 25%
Net margin (TTM) 99% · Top 25%
Operating margin (TTM) 105% · Top 25%
Growth and dividend
Revenue growth 328% · Top 25%
Dividend yield (TTM) 4.0% · Below median
Balance sheet
Debt / equity 0.05× · Below median

Valuation Multiplesvs Asset Management median · lower = cheaper

P/E (TTM) 5.6× · Cheapest 25%
P/B 1.10× · Pricier than median
P/S (TTM) 7.36× · Pricier than median
EV/EBITDA 7.8× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)100 · sector 55
FUTURE (revenue growth)100 · sector 20
PAST (return on equity)62 · sector 22
HEALTH (low debt)97 · sector 95
DIVIDEND (yield)79 · sector 80

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Asset Management stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Blackstone Inc BX $124.01 $52.88 −57%
Brookfield Corporation BN $37.85 $13.75 −64%
KKR & Co KKR $98.44 $19.97 −80%
Apollo Global Management, Inc APO $124.15 $229.64 +85%
State Street Corporation STT $180.25 $138.33 −23%
Ameriprise Financial, Inc AMP $512.37 $579.51 +13%
Ares Management Corporation ARES $124.72 $119.25 −4%
Northern Trust Corporation NTRS $173.40 $122.02 −30%
Raymond James Financial, Inc RJF $159.39 $312.27 +96%
T. Rowe Price Group TROW $104.17 $208.34 +100%

Explore undervalued stocks

More undervalued Financial Services stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "HBM Healthcare Investments Fair Value". https://www.fairvalue-calculator.com/stock/HBMN

Frequently asked questions

Is HBM Healthcare Investments (HBMN) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of CHF 379.49 versus a price of CHF 227.00, about +67% upside (undervalued).
What is the fair value of HBMN?
Our model-based fair value for HBM Healthcare Investments is CHF 379.49 (as of Sep 24, 2026), built from audited fundamentals. The current price: CHF 227.00.
What is the quality score of HBMN?
HBM Healthcare Investments has a Quality Score of 79/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for HBM Healthcare Investments (HBMN)?
Our model-based price target is the fair value of CHF 379.49 (as of Sep 24, 2026) from 8 valuation models. Cautious scenario CHF 277.68, optimistic scenario CHF 1,286. It is a calculation from audited fundamentals, not an analyst target.
What is the HBM Healthcare Investments stock forecast for 2026?
Our models put fair value at CHF 379.49, about +67% upside versus a price of CHF 227.00 (undervalued). Cautious scenario CHF 277.68, optimistic scenario CHF 1,286. The calculation is refreshed regularly with new filings.
What is the revenue of HBM Healthcare Investments (HBMN)?
HBM Healthcare Investments reported trailing-twelve-month revenue of about CHF 276M (latest available figure, as of Sep 24, 2026).
Does HBM Healthcare Investments pay a dividend?
HBM Healthcare Investments currently shows a dividend yield of about 3.96% relative to its recent price (as of Sep 24, 2026).
What is the intrinsic value of HBM Healthcare Investments (HBMN)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For HBM Healthcare Investments it is CHF 379.49 per share (as of Sep 24, 2026), against a price of CHF 227.00. It is the blended result of 8 valuation models (cash flow, earnings, asset, dividend).
Is HBM Healthcare Investments stock overvalued or undervalued in 2026?
As of Sep 24, 2026, HBMN trades below its calculated fair value: price CHF 227.00, fair value CHF 379.49, a gap of about +67% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of HBMN?
No. The price is what the market pays today (CHF 227.00); the fair value is what the company's own numbers justify (CHF 379.49). For HBM Healthcare Investments the two are CHF 152.49 per share apart. That gap is exactly why we show both numbers side by side.
How much is HBM Healthcare Investments worth?
The market values HBM Healthcare Investments at about CHF 1.7B (market capitalisation, as of Sep 24, 2026). Per share that is CHF 227.00; our models calculate a fair value of CHF 379.49 per share.
What do the bullish and bearish scenarios say about HBMN?
Our models span a range for HBM Healthcare Investments: cautious scenario CHF 277.68, base CHF 379.49, optimistic CHF 1,286 per share (as of Sep 24, 2026, price CHF 227.00). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of HBMN?
HBM Healthcare Investments trades at a price-to-earnings ratio of 5.6 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of CHF 379.49 is built from several models across several years. Other multiples: P/B 1.1, P/S 7.4, EV/EBITDA 7.8.
How solid is the balance sheet of HBM Healthcare Investments (HBMN)?
Balance-sheet figures for HBM Healthcare Investments (as of Sep 24, 2026): return on equity 15.6%, debt of 0.05 per unit of equity. They feed the Quality Score of 79/100, which measures business quality independently of the share price.
How far is HBMN from its 52-week high?
HBM Healthcare Investments trades at CHF 227.00, about 11% below its 52-week high of CHF 255.50 and 34% above the low of CHF 169.41 (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of CHF 379.49 is for.
Which stocks are comparable to HBM Healthcare Investments?
From the same area (Financial Services) we also value Blackstone Inc, Brookfield Corporation, KKR & Co, Apollo Global Management, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is HBM Healthcare Investments stock attractive at the current price?
The data as of Sep 24, 2026: price CHF 227.00, calculated fair value CHF 379.49 (+67%), Quality Score 79/100, from 8 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of HBMN calculated?
We run HBM Healthcare Investments through 8 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of CHF 379.49, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. HBM Healthcare Investments currently trades 67 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of HBM Healthcare Investments (HBMN)?
The closing price on Sep 23, 2026 was CHF 227.00. Our model-based fair value is CHF 379.49, about +67% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with HBM Healthcare Investments right now?
The rarer combination: high quality (79/100) AND below fair value. That earns a closer look rather than a quick verdict. The price is below even our cautious bear case (CHF 277.68). The market is more pessimistic than our downside scenario. The model range is unusually wide (CHF 277.68 to CHF 1,286). The outcome hinges heavily on assumptions, so read the point estimate with caution. For a financial, book-value and earnings-based methods matter more than a cash-flow DCF, which fits banks and insurers poorly.

Key figures of HBM Healthcare Investments

How large is the market capitalisation of HBM Healthcare Investments (HBMN)?
The market capitalisation of HBM Healthcare Investments is CHF 1.7B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of HBM Healthcare Investments (HBMN)?
The price-to-sales ratio of HBM Healthcare Investments is 5.52 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of HBM Healthcare Investments (HBMN)?
Earnings per share at HBM Healthcare Investments are CHF 40.74 (price ÷ EPS = P/E 5.6). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of HBM Healthcare Investments (HBMN)?
The dividend yield of HBM Healthcare Investments is 4.0% (payout 22.1%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of HBM Healthcare Investments (HBMN)?
The net margin of HBM Healthcare Investments is 99.1% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of HBM Healthcare Investments (HBMN)?
The return on equity (ROE) of HBM Healthcare Investments is 15.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of HBM Healthcare Investments (HBMN)?
On an EBIT basis the return on assets of HBM Healthcare Investments is −2.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of HBM Healthcare Investments (HBMN)?
The operating margin of HBM Healthcare Investments is 105% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at HBM Healthcare Investments (HBMN)?
Revenue at HBM Healthcare Investments is growing +328% versus a year earlier. How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at HBM Healthcare Investments (HBMN)?
Earnings per share at HBM Healthcare Investments are growing +343% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does HBM Healthcare Investments (HBMN) generate?
The free cash flow of HBM Healthcare Investments is −CHF 2.7M (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does HBM Healthcare Investments (HBMN) carry?
The net debt of HBM Healthcare Investments is CHF 94.3M (fiscal year 2026). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch HBM Healthcare Investments in the live analysis

One click puts HBM Healthcare Investments on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.